



WEST VIRGINIA SECRETARY OF STATE

KRIS WARNER

ADMINISTRATIVE LAW DIVISION

eFILED

5/4/2026 3:30:20 PM

Office of West Virginia
Secretary Of State

**NOTICE OF FINAL FILING AND ADOPTION OF A LEGISLATIVE RULE AUTHORIZED
BY THE WEST VIRGINIA LEGISLATURE**

AGENCY: Pharmacy TITLE-SERIES: 15-01
RULE TYPE: Legislative Amendment to Existing Rule: Yes Repeal of existing rule: No
RULE NAME: LICENSURE AND PRACTICE OF PHARMACY
CITE STATUTORY AUTHORITY: §30-5-7

The above rule has been authorized by the West Virginia Legislature.

Authorization is cited in (house or senate bill number) HB 4265

Section §64-9-17(a) Passed On 3/14/2026 12:00:00 AM

This rule is filed with the Secretary of State. This rule becomes effective on the following date:

July 1, 2026

This rule shall terminate and have no further force or effect from the following date:

August 01, 2031

BY CHOOSING 'YES', I ATTEST THAT THE PREVIOUS STATEMENT IS TRUE AND CORRECT.

Yes

Krista Capehart -- By my signature, I certify that I am the person authorized to file legislative rules, in accordance with West Virginia Code §29A-3-11 and §39A-3-2.

15CSR1

TITLE 15
LEGISLATIVE RULE
WEST VIRGINIA BOARD OF PHARMACY

SERIES 1
LICENSURE AND PRACTICE OF PHARMACY

§15-1-1. General.

- 1.1. Scope. -- Licensure and practice of pharmacist care.
- 1.2. Authority -- W. Va. Code §30-5-7.
- 1.3. Filing date -- May 4, 2026.
- 1.4. Effective date -- July 1, 2026.
- 1.5. Sunset Provision-- This rule shall terminate and have no further force or effect on August 1, 2031.

§15-1-2. Definitions.

- 2.1. The following words and phrases as used in this Rule mean:

2.1.1. "Abortifacient" means any chemical or drug prescribed or dispensed with the intent of causing an abortion.

2.1.2. "Accredited School of Pharmacy" means a school of pharmacy accredited by the American Council on Pharmaceutical Education (ACPE), or a recognized school of pharmacy located outside of the United States or its territories (a foreign school of pharmacy) which pharmacy education is found by the Board to be equivalent to an ACPE accredited school by a graduate from the foreign school of pharmacy obtaining a Foreign Pharmacy Graduate Examination Committee Certificate (FPGEC) from the National Association of Boards of Pharmacy (NABP).

2.1.3. "Act" or "Uniform Controlled Substance Act" means Chapter 60A of the West Virginia Code.

2.1.4. "Administer" means the direct application of a drug to the body of a patient or research subject by injection, inhalation, ingestion or any other means.

2.1.5. "Automated pharmacy system" means mechanical systems which perform operations or activities, other than compounding or administration, relative to the storage, packaging, dispensing, or distribution of medications, and which collect, control, and maintain all transaction information.

2.1.6. "Beyond-use date" means a date placed on a medication package or prescription label at the time of dispensing or repackaging that is intended to indicate the time beyond which the contents are not recommended to be used.

2.1.7. "Board" means the West Virginia Board of Pharmacy.

2.1.8. "Board authorization" means a license, registration or permit issued under W. Va. Code §30-5-1 *et seq.* and this rule.

15CSR1

2.1.9. "Compounding" means:

2.1.9.a. The preparation, mixing, assembling, packaging, or labeling of a drug or device:

2.1.9.a.1. As the result of a practitioner's prescription drug order or initiative based on the practitioner/patient/ pharmacist relationship in the course of professional practice for sale or dispensing, or

2.1.9.a.2. For the purpose of, or as an incident to, research, teaching or chemical analysis and not for sale or dispensing, and

2.1.9.b. The preparation of drugs or devices in anticipation of prescription drug orders based on routine, regularly observed prescribing patterns.

2.1.9.c. The following are not "compounding" and are exempt from USP 795 Compounding Standards:

2.1.9.c.1. The reconstitution of a drug pursuant to a manufacturer's directions;

2.1.9.c.2. The act of tablet splitting, crushing, or capsule opening; except those prohibited by USP General Chapter 800 Hazardous Drugs;

2.1.9.c.3. Upon the request of the prescribing practitioner and/or the patient for whom the prescription is ordered or such patient's agent, the addition of therapeutically inert, nonallergenic flavoring agents to a commercially manufactured product, not in excess of five percent (5%) of the preparation's total volume;

2.1.9.c.4. The combining of commercially manufactured ready to use products under the following conditions:

2.1.9.c.4.A. No more than four (4) commercially manufactured ready-to-use products are combined;

2.1.9.c.4.B. All products combined are FDA approved;

2.1.9.c.4.C. Combining is not done in anticipation of medication orders;

2.1.9.c.4.D. USP 795 beyond use dating (BUDs) is followed;

2.1.9.c.4.E. Combining with hazardous drugs from final dosage forms, listed in NIOSH List Tables 2 and 3 requires assessment of risk, the pharmacist or pharmacy technician should wear personal protective equipment as described in USP Chapter 800 and must use compounding equipment dedicated solely for hazardous drugs;

2.1.9.c.4.F. A valid prescription shall serve as the combining record, including the name and amount or concentration, lot number, and expiration date of each ingredient; and

2.1.9.c.4.G. The prescription label shall comply with the labeling requirements as set forth in 15 C.S.R. 01.

2.1.10. "Confidential information" means patient-identifiable information maintained by any person in connection with the practice of pharmacist care in the patient record or which is communicated to the patient as part of patient counseling, or which is communicated by the patient to the person providing

pharmacist care.

2.1.11. "Controlled Substance" means a drug, substance, or immediate precursor in Schedule I through Schedule V of either the Federal Controlled Substances Act, 21 U.S.C § 801 *et seq.*, or the West Virginia Uniform Controlled Substances Act, Chapter 60A of the West Virginia Code.

2.1.12. "Cosmetic" means:

2.1.12.a. Articles intended to be rubbed, poured, sprinkled or sprayed on, introduced into, or otherwise applied to the human body, or any part of the human body for cleansing, beautifying, promoting attractiveness or temporarily altering the appearance;

2.1.12.b. Articles intended for use as a component of those articles, except that the term shall not include soap; and

2.1.12.c. Shall be held to include "dentifrice" and "toilet articles."

2.1.13. "Deliver" or "delivery" means the actual, constructive or attempted transfer of a drug or device from one person to another, whether or not for a consideration.

2.1.14. "Device" means an instrument, apparatus, implement or machine, contrivance, implant or other similar or related article, including any component part or accessory, which is required under federal law to bear the label, "Caution: Federal or state law requires dispensing by or on the order of a physician" or the language or symbol as determined by the U. S. Food and Drug Administration.

2.1.15. "Direct supervision" means that a licensed pharmacist is physically present in the pharmacy and is available to verify the accuracy of a prescription before it is dispensed.

2.1.16. "Dispense" or "dispensing" means the interpretation, evaluation, and implementation of a prescription drug order, including the preparation, verification and delivery of a drug or device to a patient or patient's agent in a suitable container appropriately labeled for subsequent administration to, or use by, a patient.

2.1.17. "Distribute" or "Distribution" means to sell, offer to sell, deliver, offer to deliver, broker, give away, or transfer a drug, whether by passage of title, physical movement, or both. The term does not include:

2.1.17.a. To dispense or administer;

2.1.17.b. Delivering or offering to deliver a drug by a common carrier in the usual course of business as a common carrier; or providing a drug sample to a patient by a practitioner licensed to prescribe such drug;

2.1.17.b.1. A health care professional acting at the direction and under the supervision of a practitioner; or the pharmacy of a hospital or of another health care entity that is acting at the direction of such a practitioner and that received such sample in accordance with the Prescription Drug Marketing Act and regulations to administer or dispense;

2.1.17.b.2. Intracompany sales.

2.1.18. "Distributor" means a person licensed as a wholesaler or third-party logistics provider.

15CSR1

2.1.19. "Drug" means:

2.1.19.a. Articles recognized as drugs by the United States Food and Drug Administration, or in any official compendium, or supplement;

2.1.19.b. An article, designated by the board, for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or other animals;

2.1.19.c. Articles, other than food, intended to affect the structure or any function of the body of humans or other animals; and

2.1.19.d. Articles intended for use as a component of any articles specified in paragraph 2.1.19.a., 2.1.19.b., or 2.1.19.c. of this subdivision.

2.1.20. "Drug regimen review" includes, but is not limited to, the following activities:

2.1.20.a. Evaluation of the prescription drug orders and, if available, patient records for:

2.1.20.a.1. Known allergies;

2.1.20.a.2. Rational therapy-contraindications;

2.1.20.a.3. Reasonable dose and route of administration; and

2.1.20.a.4. Reasonable directions for use.

2.1.20.b. Evaluation of the prescription drug orders and patient records for duplication of therapy.

2.1.20.c. Evaluation of the prescription drug for interactions and/or adverse effects which may include, but are not limited to, any of the following:

2.1.20.c.1. Drug-drug;

2.1.20.c.2. Drug-food;

2.1.20.c.3. Drug-disease; and

2.1.20.c.4. Adverse drug reactions.

2.1.20.d. Evaluation of the prescription drug orders and if available, patient records for proper use, including overuse and underuse and optimum therapeutic outcomes.

2.1.21. "Electronic data intermediary" means an entity that provides the infrastructure to connect a computer system, hand-held electronic device or other electronic device used by a prescribing practitioner with a computer system or other electronic device used by a pharmacist to facilitate the secure transmission of:

2.1.21.a. An electronic prescription order;

2.1.21.b. A refill authorization request;

15CSR1

2.1.21.c. A communication; or

2.1.21.d. Other patient care information.

2.1.22. "E-prescribing" means the transmission, using electronic media, of prescription or prescription-related information between a practitioner, pharmacist, pharmacy benefit manager or health plan as defined in 45 CFR §160.103, either directly or through an electronic data intermediary. E-prescribing includes, but is not limited to, two-way transmissions between the point of care and the pharmacist. E-prescribing may also be referenced by the terms "electronic prescription" or "electronic order".

2.1.23. "Electronic supervision" means that a licensed pharmacist provides supervision of the pharmacy through the utilization of audio and visual technology, which may be used with both direct and indirect supervision tasks of a pharmacy technician or pharmacy technician trainee.

2.1.24. "Expiration date" means the time assigned by manufacturers based on analytical and performance testing of the sterility, chemical and physical stability, and packaging integrity of the product during which it can be expected to meet the requirements of a compendial monograph, if one exists, or is guaranteed to be safe and potent provided it is kept under the prescribed storage conditions.

2.1.25. "Gender altering medication" means the prescribing or administering of the following for the purpose of assisting an individual with a gender transition:

2.1.25.a. Gonadotropin-releasing hormone (GnRH) analogues or other puberty blocking medication to stop or delay normal puberty; and

2.1.25.b. Supraphysiologic doses of testosterone, estrogen, or other androgens than would normally be produced endogenously in a healthy individual of the same age and sex.

2.1.26. "Inpatient pharmacy" means the area within a licensed institution; i.e., a hospital, or other place where patients stay at least one night, where drugs are stored and dispensed to other areas of the institution for administration to the patients by other licensed health care providers.

2.1.27. "Inspector" means an agent of the Board, who is a licensed pharmacist, appointed by the Board to conduct periodic inspections of board authorization holders and perform other duties as designated by the Board.

2.1.28. "Institutional facility" means any organization whose primary purpose is to provide a physical environment for patients to obtain health care services, including but not limited to a hospital, convalescent home, nursing home, extended care facility, mental health facility, rehabilitation center, psychiatric center, developmental disability center, drug abuse treatment center, family planning clinic, correctional facility, hospice, public health facility, or athletic facility.

2.1.29. "Institutional pharmacy" means that physical portion of an institutional facility that is engaged in the compounding, dispensing, and distribution of drugs, devices, and other materials used in the diagnosis and treatment of injury, illness, and disease and which holds a pharmacy license from the Board.

2.1.30. "Intern" or "pharmacy intern" means an individual who is currently licensed by the board to engage in the practice of pharmacist care while under the supervision of a pharmacist.

2.1.31. "Labeling" means the process of preparing and affixing a label to a drug container exclusive, however, of a labeling by a manufacturer, packer or distributor of a nonprescription drug or commercially

packaged prescription drug or device.

2.1.32. "Mail order pharmacy" means a pharmacy, regardless of its location, which dispenses greater than twenty-five percent (25%) prescription drugs via the mail or other delivery services.

2.1.33. "Manufacturer" means any person who is engaged in manufacturing, preparing, propagating, processing, packaging, repackaging or labeling of a prescription drug, whether within or outside this state.

2.1.34. "Manufacturing" means the production, preparation, propagation or processing of a drug or device, either directly or indirectly, by extraction from substances of natural origin or independently by means of chemical or biological synthesis and includes any packaging or repackaging of the substance or substances or labeling or relabeling of its contents and the promotion and marketing of the drugs or devices. Manufacturing also includes the preparation and promotion of commercially available products from bulk compounds for resale by pharmacies, practitioners, or other persons.

2.1.35. "Nonprescription drug" means a drug which may be sold without a prescription and which is labeled for use by the consumer in accordance with the requirements of the laws and rules of this state and the federal government.

2.1.36. "Nuclear pharmacist" means a pharmacist who has been certified in the specialty of nuclear pharmacy.

2.1.37. "Nuclear pharmacy" means a place where radioactive drugs are prepared and dispensed and which operates under specialized rules.

2.1.38. "Original License" means a license issued by the Board to an applicant when:

2.1.38.a. The applicant is a new business;

2.1.38.b. The applicant is an established business that is transferred to a successor;

2.1.38.c. The applicant is an established business in which fifty percent (50%) ownership or more is transferred to a new owner;

2.1.38.d. The applicant is an established business in which control of pharmaceutical services is transferred; not including a change in pharmacist-in-charge; or

2.1.38.e. The applicant is an established business which moves to a new location.

2.1.39. "Outpatient pharmacy" means any pharmacy, apothecary, or place within this state where drugs are dispensed and sold at retail or displayed for sale at retail and where the practice of pharmacy is conducted and pharmacist care is provided; and any place outside of this state where drugs are dispensed and the practice of pharmacy and pharmacist care is provided to residents of this state.

2.1.40. "Over-the-counter drug" or "OTC drug" means any drug that is not a prescription drug or prescription drug.

2.1.41. "Patient counseling" means the communication by the pharmacist of information, as prescribed further in the rules of the board, to the patient to improve therapy by aiding in the proper use of drugs and devices.

15CSR1

2.1.42. "Person" means an individual, corporation, partnership, association or any other legal entity, including government.

2.1.43. "Person Addicted" means one who has acquired the habit of using alcoholic beverages or controlled substances or other agents to such an extent as to deprive him or her of reasonable self-control.

2.1.44. "Pharmacist care" means the provision by a pharmacist of patient care activities, with or without the dispensing of drugs or devices, intended to achieve outcomes related to the cure or prevention of a disease, the elimination or reduction of a patient's symptoms, or the arresting or slowing of a disease process, and as provided in W. Va. Code §30-5-10.

2.1.45. "Pharmacist" means an individual currently licensed by this state to engage in the practice of pharmacist care.

2.1.46. "Pharmacist-in-charge" means a pharmacist currently licensed in this state who:

2.1.46.a. Accepts responsibility for the operation of a pharmacy in conformance with all state and federal laws and rules pertinent to the practice of pharmacist care and the distribution of drugs;

2.1.46.b. Has the responsibility for the practice of pharmacist care, as defined in this rule, at the pharmacy for which he or she is pharmacist-in-charge. The pharmacy permit holder has responsibility for all other functions, administrative and operational, of the pharmacy. The pharmacist-in-charge may advise the pharmacy permit holder in writing of administrative and operational matters. The pharmacist-in-charge is not legally responsible if the permit holder does not follow the written advice;

2.1.46.c. Works at least 30 hours a week, with the pharmacist-in-charge working at least three days per week, in that pharmacy, including the use of any accrued annual or sick leave; Provided That, in any pharmacy which is open on average less than 40 hours per week in a calendar year, he or she must work in the pharmacy a majority of the hours that the pharmacy is open (e.g., if open 20 hours per week, the pharmacist-in-charge must work 11 hours per week within the pharmacy); and

2.1.46.d. With regards to a pharmacist-in-charge in a Charitable Clinic Pharmacy, this position may be filled by a committee of up to 3 pharmacists who accept as a group the responsibilities of the required pharmacist-in-charge. Further notwithstanding the requirements of subsection c, above, with regard to a Charitable Clinic Pharmacy, if the pharmacy is open an average of more than 40 hours per week, the pharmacist-in-charge or pharmacist-in-charge committee must work at least eight hours per calendar month; if the pharmacy is open on average at least 30 and up to 40 hours per week, the pharmacist-in-charge or pharmacist-in-charge committee must work in the charitable clinic pharmacy at least six hours per calendar month; if the pharmacy is open on average at least 15 and up to 30 hours per week, the pharmacist-in-charge or pharmacist-in-charge committee must work in the charitable clinic pharmacy at least four hours per calendar month; if the charitable clinic pharmacy is open on average at least five and up to 15 hours per week, the pharmacist-in-charge or pharmacist-in-charge committee must work in the charitable clinic pharmacy at least two hours per calendar month; and, if the charitable clinic pharmacy is open less than five hours per week, the pharmacist-in-charge or pharmacist-in-charge committee must work in the charitable clinic pharmacy the lesser of two hours per month or 50% of the hours the charitable clinic pharmacy is open.

2.1.46.d.1. Charitable Clinic
Pharmacy hours
per week

Hours required
by PIC
per month

15CSR1

| | |
|---------------|--------------------------------------|
| More than 40: | 8 |
| 30 to 40: | 6 |
| 15 to 30: | 4 |
| 5 to 15: | 2 |
| Less than 5: | The lesser of 2 or 50% of hours open |

2.1.47. "Pharmacy technician" means registered supportive personnel who work under the direct or electronic supervision of a pharmacist, and who have passed an approved training program; Provided That, in a Charitable Clinic Pharmacy, when no pharmacist is on-site, a pharmacy technician may work under the direct supervision of a prescribing practitioner who is licensed as such in the State of West Virginia.

2.1.48. "Pharmacy technician trainee" means registered supportive personnel currently engaged in a pharmacy technician training program which has been approved by the Board and who is under the direct supervision of a pharmacist.

2.1.49. "Practice of telepharmacy" means the provision of pharmacist care by properly licensed pharmacists located within United States jurisdictions through the use of telecommunications or other technologies to patients or their agents at a different location that are located within United States jurisdictions.

2.1.50. "Practitioner" or "prescribing practitioner" means an individual authorized by a jurisdiction of the United States to prescribe drugs in the course of professional practices, as allowed by law.

2.1.51. "Preceptor" means an individual who is currently licensed as a pharmacist by the board, meets the qualifications as a preceptor under the rules of the board, and participates in the instructional training of pharmacy interns.

2.1.52. "Prescription drug" means any human drug required by federal law or regulation to be dispensed only by prescription, including finished dosage forms and active ingredients subject to section 503(b) of the federal food, drug and cosmetic act.

2.1.53. "Prescription" or "Prescription order" means a lawful order from a practitioner for a drug or device for a specific patient, including orders derived from collaborative pharmacy practice, where a valid patient-practitioner relationship exists, that is communicated to a pharmacist in a pharmacy.

2.1.54. "President" means the President of the West Virginia Board.

2.1.55. "Refill" means a subsequent dispensing of the medicine ordered by the practitioner in the original prescription order, based upon the practitioner's authorization for the subsequent dispensing in that original prescription order.

2.1.56. "Renewal" means a new prescription drug order for the same medication previously prescribed for a patient, authorized by the practitioner without change or modification from the original prescription order after the authorized number of refills of the original prescription order has been exhausted.

2.1.57. "Sample" means a package of a prescription drug provided by a manufacturer on the request of a practitioner or charitable clinic to be given to a patient without charge in accordance with federal law.

2.1.58. "Secretary" means the Secretary of the West Virginia Board.

15CSR1

2.1.59. "Telehealth services" means the use of synchronous or asynchronous telecommunications technology or audio only telephone calls by a health care practitioner to provide health care services, including, but not limited to, assessment, consultation, treatment, and monitoring of a patient; transfer of medical data; patient and professional health-related education; public health services; and health administration. The term does not include internet questionnaires, e-mail messages, or facsimile transmissions.

2.1.60. "Vendor" means a private vendor which produces or supplies official state prescription paper.

2.1.61. "Vice-President" means the Vice-President of the West Virginia Board.

2.1.62. "West Virginia Official Prescription Paper" means prescription paper which meets the following criteria:

2.1.62.a. Prevention of unauthorized copying;

2.1.62.b. Prevention of erasure or modification; and

2.1.62.c. An ability to prevent counterfeit prescriptions or prescription pads.

2.1.63. "Wholesaler" is a person or entity licensed by the Board to distribute, by sales or otherwise, prescription drugs to persons other than a consumer or patient.

§15-1-3. General Provisions.

3.1. Officers of the Board. – The members of the board shall annually elect as officers of the Board one member to serve as President of the Board, one to serve as Vice-president and one to serve as Secretary, all to serve a one-year term or until their successors are elected. The election is to be held in June each year.

3.2. Official Seal – The Board hereby reaffirms and readopts, as the official seal of the Board the following: The outer circle of the seal has inscribed in it 'West Virginia Board of Pharmacy'; and the inner circle of the seal consists of a base upon which rests a graduate entwined about which there is an Aesculapius serpent and holding in balance a set of scales, an impression of which is affixed to it.

3.3. Disposition of moneys; report to auditor. – The Secretary shall receive and account for, all moneys derived by virtue of the provisions of W.Va. Code §30-1-1 *et seq.* and §30-5-1 *et seq.*, and shall pay such moneys into the State Treasury monthly on or before the 10th day of each month in which the monies are received.

3.4. Record of proceedings; registration of applicant; certified copies of records prima facie evidence, report to governor. – The Secretary of the Board shall keep a record of its proceedings and a register of all applicants for license or registration, showing for each, the date of his or her application, name, age, educational and other qualifications, place of residence, whether an examination was required, whether the applicant was rejected or a certificate of licensure or registration granted, the license or registration number, if required, and any suspension or revocation of any license or registration. The books and register of the Board shall be open to public inspection at all reasonable times, and the books and register, or a copy of any part of them, certified by the Secretary and attested by the seal of the Board, is prima facie evidence of all matters recorded by the Board.

15CSR1

3.5. Roster of licensed or registered persons. – The Secretary shall prepare and maintain a complete roster of all persons, granted a board authorization, alphabetically and by class or type and by whether within or without the state.

3.6. Power of Inspection and Investigation – The authorized agents of the Board may inspect and investigate in a lawful manner and during regular business hours all places or persons holding a board authorization. The investigation may include, but not be limited to, all inventories, invoices for prescription drugs, selling prices, and other records required by law, acts of individuals and facilities, but shall not extend to financial data or sales data other than shipment data or pricing data; unless the owner, operator or agent in charge of the controlled premises consents in writing. The board authorization holder shall allow access to selling prices only when needed for a specific investigation or inquiry by the Board regarding a particular drug.

3.7. During the course of any inspection or investigation by an agent of the Board the agent may temporarily close any holder of a board authorization upon the discovery of any of the following:

3.7.1. The ability of the pharmacist to practice pharmacist care with reasonable skill, competency, or safety to the public is impaired because the board authorization holder's cognitive, interpersonal, or psychomotor skills are affected by psychiatric, psychological, or emotional problems, or excessive alcohol or drug use or addiction; or

3.7.2. The absence of valid board authorization issued by the Board or by the absence of an available pharmacist to be on duty.

3.8. When a board authorization holder is closed under subsection 3.7.1 of this section they shall remain closed until an unimpaired pharmacist arrives on the premises or when a board authorization holder is closed under subsection 3.7.2 of this section, the permittee shall remain closed until a valid permit is obtained and on display as required by law.

3.9. Agents of the Board when acting in good faith and without malice are immune from individual civil liability while acting within the scope of their duties as such agents of the Board.

§15-1-4. Internship Requirements.

4.1. No person may practice as a pharmacy intern without being licensed by the board.

4.2. To be eligible to practice as a pharmacy intern, an applicant must:

4.2.1. Make application to the board on a form provided by the Board;

4.2.2. Pay the required application fee;

4.2.3. Meet all other requirements for licensure; and

4.2.4. Complete a criminal history records check as prescribed in 15 C.S.R. 01.

4.3. A pharmacy intern license expires on the 30th day of June, six years from the date of issue.

4.4. A legible copy of the original internship certificate of licensure shall be displayed at the place of internship.

4.5. The pharmacy intern must have the original with him or her in a readily retrievable location at any

15CSR1

pharmacy or other practice site where he or she is practicing as an intern. An intern shall produce the original intern certificate upon request of an appropriate official or agent of the board or proper law enforcement.

4.6. The Board may certify internship credit for an individual:

4.6.1. When a preceptor holds a current, valid license as a pharmacist from the board and the pharmacy intern has been issued an intern certificate;

4.6.2. When the pharmacy intern has notified the Board within 10 days of the employment as an intern;

4.6.3 When the pharmacy intern notifies the Board within 10 days subsequent to termination of any internship under a specific preceptor; and

4.6.4 When the internship is certified by the submission of a "Certification by Preceptor as to Internship" form immediately after termination of the internship. Forms are available from the board office.

4.7. No pharmacy intern shall be certified by the Board unless the intern is enrolled in or is a graduate of an accredited school of pharmacy or has met the requirements for educational equivalency by obtaining a Foreign Pharmacy Graduate Examination Committee Certification.

4.8. A pharmacy intern may receive experience credit for any period of time during which he or she is enrolled in an accredited school of pharmacy and the Board may accept and certify up to 1,500 hours of internship credit for interns participating or enrolled in a supervised internship as part of the school of pharmacy experiential education curriculum.

4.9. A pharmacy intern shall earn internship hours only for hours obtained in the practice of pharmacist care in the role of a pharmacist and in a licensed pharmacy. Hours worked in the role of a pharmacy technician will not be certified or accepted.

4.10. The Board may accept internship hours gained outside West Virginia on a letter of credit or certification from the Board of Pharmacy of the state in which the pharmacy intern acquired internship experience or from the recognized school of pharmacy from which the intern acquired internship experience. Up to one third of the internship hours may be fulfilled by an internship in a foreign country either through an accredited school of pharmacy experiential education program or as certified on a letter of credit or certification from the Board of Pharmacy or other regulatory body of the foreign state, province, or country responsible for regulation of the practice of pharmacy in the foreign location.

§15-1-5. Confidential Information.

5.1. All licensees and registrants must comply with the Health Insurance Portability and Accountability Act ("HIPAA"), 45 C.F.R. § 160, 45 C.F.R. § 162, and 45 C.F.R. § 164.

§15-1-6. Transfer of Prescription Drugs.

6.1. No prescription drug may be transferred except by the following methods:

6.1.1. Transfer of drugs without prescription.

6.1.1.a. Prescription drugs without a prescription may be transferred only to a permittee or practitioner and the transaction shall be recorded and the gross dollar value of the transfers shall not exceed

15CSR1

five percent of the total prescription drug sales revenue of either the transferor or the transferee pharmacy during any 12 consecutive month period.

6.1.1.b. The record showing transfers of prescription drugs without a prescription shall contain:

6.1.1.b.1. The name of the drug and its quantity;

6.1.1.b.2. The date of transaction;

6.1.1.b.3. The permittee or practitioner to whom the prescription drug was transferred; and

6.1.1.b.4. The selling price.

6.1.1.c. The record of the transfer shall be kept in the pharmacy and be immediately accessible within one year from the date of transfer, and available within 72 hours if between one year and five years from the date of transfer.

6.1.1.d. Any pharmacy with transfers of prescription drugs that exceed the five percent restriction set forth in paragraph 9.6.1.1a of this section shall obtain a permit to be a wholesaler. Intracompany sales and transfers of drugs by a retail pharmacy to another retail pharmacy to alleviate a temporary shortage shall not be included in calculation of the drug sales revenue.

6.1.2. Transfer of drugs with a Prescription.

6.1.2.a. Prescription drugs transferred by a practitioner's prescription order are dispensed. A prescription shall contain at least the following elements:

6.1.2.a.1. The patient's name and address and the date the prescription is written, Provided that, if the prescription is for expedited partner therapy as permitted by West Virginia Code Chapter 16, Article 4F, then the words "Expedited Partner Therapy" or the designation "EPT" may be written for the name of the patient;

6.1.2.a.2. The drug's name and quantity; and

6.1.2.a.3. Directions for use.

6.1.2.a.3.A. If the prescription is written on a practitioner's date prescription blank, the order shall contain the following:

6.1.2.a.3.A.1. The practitioner's printed name, address, professional designation and practitioner identifier number; and

6.1.2.a.3.A.2. The practitioner's signature.

6.1.2.a.3.B. If the prescription is written on an institutional prescription blank, the order shall contain the following:

6.1.2.a.3.B.1. The printed name of the practitioner and DEA number with suffix;
and

6.1.2.a.3.B.2. The practitioner's signature.

15CSR1

6.1.2.a.3.C. No sticker or other substance shall be allowed to obliterate or cover any of the information required by this subdivision.

6.2. Samples.

6.2.1. Pharmacies may not sell, purchase, or trade or offer to sell, purchase, or trade any prescription drug sample.

§15-1-7. Refilling Prescription Orders.

7.1. A pharmacist may not refill any prescription order containing a drug if the label of the original container bears the statement, "CAUTION: Federal Law Prohibits Dispensing Without Prescription", or "RX Only", unless the practitioner has authorized the refill by written notation on the original prescription order. Subsequent refill authorization shall be treated as a new prescription order.

7.2. If a prescription order is refillable, the date of the refill and the handwritten initials of the pharmacist shall be recorded upon the original written prescription order; if an Automated Data Processing System is used to document the refill, such documentation shall be completed in accordance with West Virginia Title 15 Code of State Rules Series 4.

7.3. No prescription order may be refilled after 12 months from the date of issuance by the practitioner.

7.4. The refilling of prescription orders for controlled substances is limited by provisions of the Uniform Controlled Substances Act, W. Va. Code §60A-3-308.

§15-1-8. Transferring Prescription Orders Between Pharmacies.

8.1. The pharmacist or pharmacy intern shall, upon the request of the patient, transfer the prescription information to the pharmacy designated by the patient. Pharmacy interns are prohibited from transferring controlled substances.

8.2. The transfer of original prescription order information is permissible between pharmacies if the transfer is communicated directly between pharmacists or pharmacy interns, and the following occurs:

8.2.1. The transferring pharmacist or pharmacy intern:

8.2.1.a. Writes the word "VOID" on the face of the original prescription order; for electronic prescriptions, information that the prescription has been transferred must be added to the prescription record;

8.2.1.b. Records on the reverse of the original prescription the name, address, and Drug Enforcement Administration (DEA) registry number of the pharmacy to which the prescription was transferred and the name of the pharmacist or pharmacy intern receiving the prescription information; for electronic prescriptions, information that the prescription has been transferred must be added to the prescription record; and

8.2.1.c. Records the date and time of the transfer and his or her first and last name;

8.2.2. The pharmacist or pharmacy intern receiving the transferred prescription order information:

8.2.2.a. Writes the word "TRANSFER" on the face of the transferred prescription; and

8.2.2.b. Provides all the information required to be on a prescription and includes:

15CSR1

8.2.2.b.1. Date of issuance of the original prescription;

8.2.2.b.2. Number of refills on the original prescription;

8.2.2.b.3. The date the original prescription was dispensed;

8.2.2.b.4. The number of valid refills remaining and date of last refill;

8.2.2.b.5. The pharmacy's name, address, DEA registry number and the original prescription number from which the prescription was transferred; and

8.2.2.b.6. The first and last name of the transferring pharmacist or pharmacy intern;

8.2.3. A pharmacist or pharmacy intern may give a copy of a prescription clearly marked "For Information Only" to a patient; and

8.2.4. A computer record may be used if it reflects the fact that the original prescription order has been voided and shall contain all the other information required in this subsection.

8.3. No pharmacy shall refuse to transfer information about a prescription to another pharmacy when requested by a patient. A pharmacy shall transfer prescription information in accordance with this rule as soon as possible in order to assure that the patient's drug therapy is not interrupted.

8.4. Information on a prescription is the property of the patient and is intended to authorize the dispensing of a specific amount of medication for the use by the patient. Pharmacies shall maintain original and transferred prescription drug orders for a period of five years from the date of the last refill; maintained on-site for a period of 12 months from last of last refill, and available within 72 hours of request if date of last refill is between one and five years.

8.5. Pharmacies accessing a common electronic file or database used to maintain required dispensing information are not required to transfer prescription drug orders or information for dispensing purposes between or among pharmacies participating in the same common prescription file. Provided, the common electronic file or database shall contain complete records of each prescription drug order and refill dispensed, and the system shall have the capability at the pharmacy refilling the prescription drug order or at the pharmacy where the prescription is transferred to generate a hard copy record of each prescription drug order transferred or accessed for purposes of refilling.

8.6. After direct communication between pharmacists or pharmacy interns or between a pharmacist and pharmacy intern confirming the prescription transfer, the required prescription order information may be transferred via facsimile.

§15-1-9. Returning Drugs and Devices.

9.1. No pharmacist or pharmacy shall accept from a patient or other person, except for the purpose of destruction, any part of any unused prescription drug unless:

9.1.1. The returned drugs are in a manufacturer's original, sealed and visibly tamperproof container;

9.1.2. The returned drugs are in extemporaneously prepared unit dose packaging, as defined in this rule, and are returned within an institution or by an institution; and

9.1.3. All drugs are identified as to lot and control number and expiration date.

9.2. No controlled substance that has been dispensed may be returned and placed in stock for reuse or resale under any circumstances. However, any entity registered pursuant to 15 C.S.R. 02 which is properly registered with the DEA as an authorized collector to receive the transfer from ultimate users of any unwanted and unused pharmaceutical controlled substances in their lawful possession for safe, secure, and responsible disposal, may receive returns of controlled substances for such disposal.

9.3. Any drugs returned within or by an institution shall be recorded in a log which lists the name of the patient, the name and strength of the drug with the name of its manufacturer, the prescription number (if applicable), the amount of the drug returned and the date of the return. The log shall contain the signatures of the receiving pharmacist and a registered nurse employed by the facility and the log shall be retained for at least two years.

9.4 Drugs must be returned in compliance with a Donated Drug Repository Program as permitted in W. Va. Code §60B-1-1 *et seq.* and 15 C.S.R. 20.

§15-1-10. Drug Product Selection and Substitution.

10.1. The Board adopts the drug products in the Approved Drug Products with Therapeutic Equivalence Evaluations published by the Food and Drug Administration, Center for Drug Evaluation and Research, (commonly called the “Orange Book”) with “AA”, “AB”, “AN”, “AO”, “AP”, or “AT” ratings and any authorized generics as acceptable products for generic substitution as required by W. Va. Code §30-5-12b. The Board may approve drug products not listed in the Orange Book as acceptable products for generic substitution upon submission of a written request to the Board.

§15-1-11. Equipment, Facilities and Record Systems.

11.1. The Board shall not issue a registration to operate a pharmacy unless the necessary professional, physical, and technical equipment requirements have been fulfilled.

11.1.1. The pharmacy shall have a separate area available for patient counseling which will ensure the privacy and confidentiality of the discussions; and which has adequate space to use any equipment, visual aids, and publications, if necessary, to provide proper counseling. This subdivision does not apply to pharmacies which have been granted a registration prior to the effective date of this provision of May 1, 1999 or inpatient pharmacies.

11.1.2. All standards set by the United States Pharmacopeial Convention (“USP”) are the minimum standards followed by all licensed pharmacists and pharmacies during the course of the professional practice of pharmacist care.

11.2. A pharmacy shall continually possess the following:

11.2.1. A sanitary method of measuring and dispensing between five and 250 milliliters of liquids;

11.2.2. Supplies necessary to ensure the physical, equipment, and environmental requirements established by USP;

11.2.3. For a pharmacy compounding ophthalmic preparations, IV additives, enteral nutritional products or other pharmaceuticals requiring more sophisticated techniques, the proper equipment and facilities to prepare sterile products and meet the requirements of good compounding practice;

15CSR1

11.2.4. Adequate facilities for the proper storage of pharmaceuticals. All areas where drugs and devices are stored shall be dry, well-lighted, well-ventilated, and maintained in a clean and orderly condition. Storage areas shall be maintained at temperatures which will ensure the integrity of the drugs prior to their dispensing as stipulated by the USP and/or the manufacturer's or distributor's labeling unless otherwise indicated by the Board;

11.2.5. Facilities for the safe storage of controlled substances if the dispersion method is not used;

11.2.6. An acceptable system of keeping records of prescriptions dispensed as required by the Uniform Controlled Substance Act and any Rules and Regulations pertaining to the Act;

11.2.7. A system of keeping patient profiles as required by 15 C.S.R. 04; and

11.2.8. The most currently available Pharmacy Law Book and book of Rules and Regulations published by the Board, provided that a readily retrievable electronic copy may suffice.

§15-1-12. Sterile Pharmaceutical Compounding.

12.1. Permitting and Control.

12.1.1. A pharmacy compounding or mixing prescription orders for sterile solutions or suspensions shall obtain a Sterile Pharmaceutical Compounding Permit from the Board in addition to a pharmacy license. The Board shall issue a permit after a satisfactory inspection of the completed facilities.

12.1.2. The compounding and preparation of sterile prescription orders shall be accomplished in a pharmacy environment subject to the West Virginia Code and the Rules of this Board and all Federal laws and regulations.

12.1.3. Sterile compounding or mixing shall be under the supervision and control of a pharmacist who shall be present on duty during all hours of prescription preparation.

12.2. An applicant for a Sterile Pharmaceutical Compounding Permit shall provide the Board with the following:

12.2.1. A completed Board application form;

12.2.2. A copy of the Policy and Procedure Manual;

12.2.3. Statement and plans showing how the applicant meets the minimum requirements regarding space, equipment, supplies, and publications.

12.3. The compounding environment for this practice shall be separate rooms set apart from all other activities. The environment shall facilitate controlled aseptic conditions and meet all the following standards of:

12.3.1. The 2023 United States Pharmacopeia (USP) Chapter 797 Pharmaceutical Compounding – Sterile Preparations;

12.3.2 The 2023 United States Pharmacopeia (USP) Chapter 800 Hazardous Drugs; and

12.3.3. The Controlled Environment Testing Association's (CETA) Certification Guide for Sterile Compounding Facilities or a substantially similar standard for certification completed by a qualified independent certifier indicating that the compounding area is meeting its design and air quality

specifications.

12.4. General Requirements.

12.4.1. Special handling and packaging shall be available to maintain stability of the prepared prescription orders during delivery to the patient.

12.4.2. All prescriptions shall include labeling, in addition to that required by other state or federal law or rule, showing:

12.4.2.a. The drug's beyond-use date;

12.4.2.b. The date of preparation; and

12.4.2.c. The drug's control number.

12.4.3. A pharmacy with a Sterile Pharmaceutical Compounding Permit shall provide a 24-hour telephone number to allow its patients or other health care providers who may be administering its prescriptions to contact its pharmacists.

12.5. Reference Works. Minimum reference works required in a pharmacy with a Sterile Pharmaceutical Compounding:

12.5.1. A current edition, in either print or electronic media, of a drug information and reference compendium such as Elsevier Gold Standard/Clinical Pharmacology, Facts & Comparisons, or other appropriate compendium approved by the board; and

12.5.2. Handbook of Injectable Drugs published by the American Society of Health System Pharmacists, or its equivalent.

§15-1-13. Licensure and Control of Nuclear Pharmacies.

13.1. General Requirements.

13.1.1. A pharmacy providing radiopharmaceutical services, and compounding or mixing prescription orders for radiopharmaceuticals shall obtain a Nuclear Pharmacy registration from the Board. The license will be issued after satisfactory inspection of the completed facilities. The license will be issued only when the pharmacist-in-charge is a qualified nuclear pharmacist and the pharmacy has been approved by the appropriate federal agency.

13.1.2. Pharmacies providing regular pharmacist care in addition to radiopharmaceutical services shall comply with all sections of this rule applicable to pharmacies in general.

13.2. Space.

13.2.1. The nuclear pharmacy area shall be separate from all other pharmacy areas for non-radioactive drugs and shall be secured from unauthorized personnel.

13.2.2. A pharmacy handling radiopharmaceuticals shall provide a radioactive storage and product decay area which meets the requirements of the appropriate federal agency and the 2023 United States Pharmacopeia (USP) Chapter 825 Radiopharmaceuticals.

13.3. Dispensing and labeling.

15CSR1

13.3.1. A prescription order for a radiopharmaceutical shall be dispensed in a package that is properly labeled. A pharmacy may furnish radiopharmaceuticals only to practitioners for administration to patients and for the occasional transfer to another pharmacist.

13.3.2. In addition to any label requirements of the Board for nonradioactive drugs, the immediate outside container of a radiopharmaceutical to be dispensed shall also be labeled with:

- 13.3.2.a. The standard radiation symbol;
- 13.3.2.b. The words “CAUTION-Radioactive Material”;
- 13.3.2.c. The name of the radio nucleotide;
- 13.3.2.d. The chemical form;
- 13.3.2.e. The amount of radioactive material contained in millicuries or microcuries;
- 13.3.2.f. The volume in milliliters, if the material is a liquid;
- 13.3.2.g. The requested calibration time for the amount of radioactivity contained; and
- 13.3.2.h. The practitioner’s name and the assigned lot number.

13.3.3. The immediate inner container shall be labeled with:

- 13.3.3.a. The standard radiation symbol;
- 13.3.3.b. The words “CAUTION-Radioactive Material”; and
- 13.3.3.c. The prescription number

13.3.4. The amount of radioactivity shall be determined by radiometric methods for each dose immediately prior to dispensing.

13.4. Distribution – Nuclear pharmacies may distribute approved radioactive drugs to any receiving pharmacy if the receiving pharmacy does not process the radioactive drugs in any manner nor violate or change the product packaging except that a licensed pharmacist may divide the product into individual doses.

§15-1-14. Sanitary Regulation of Pharmacies.

14.1. The pharmacy shall have undergone a pharmacy inspection by the Board or authorized agent thereof; and possess the following minimum requirements for a pharmacy:

14.1.1. Each Pharmacy shall be of sufficient size, as determined by the Board, to allow for the safe and proper storage of Prescription Drugs and for the safe and proper Compounding and/or preparation of Prescription Drug Orders.

14.1.2. Each Pharmacy shall maintain an area designated for the provision of Patient Counseling services. This area shall be designed to provide a reasonable expectation of privacy of Protected Health Information.

15CSR1

14.1.3. The prescription counter shall be used for no other purpose than for the compounding and dispensing of prescriptions and shall be maintained free from dust and in an orderly condition.

14.1.4. All pharmacist and pharmacy interns when providing pharmacist care, shall wear a name tag identifying the individual and showing their job designation, and are required to keep themselves and their apparel in clean condition. All pharmacy technicians and pharmacy technician trainees shall wear a name tag identifying the individual and showing their job designation and shall wear clean attire. Provided, that only pharmacists and pharmacy interns may wear a white coat or jacket.

14.1.5. All areas where Drugs and Devices are stored shall be dry, well lighted, well ventilated, and maintained in a clean and orderly condition. Storage areas shall be maintained at temperatures which will ensure the integrity of the Drugs prior to their Dispensing as stipulated by the United States Pharmacopeia–National Formulary (USP-NF) and/or the Manufacturer’s or Distributor’s Product Labeling unless otherwise indicated by the Board.

14.1.6. Each Pharmacy shall have access to a sink with hot and cold running water that is convenient to the prescription preparation, patient care, and compounding area for the purpose of hand scrubs prior to pharmacist care.

14.1.7. The Pharmacy shall carry and utilize the equipment and supplies necessary to conduct a Pharmacy in a manner that is in the best interest of the patients served and to comply with all State and Federal laws.

14.1.8. The Pharmacy shall provide a means for patients to prevent disclosure of Confidential Information or personally identifiable information that was obtained or collected by the Pharmacist or Pharmacy incidental to the Delivery of Pharmacist Care Services other than as authorized by law or rules of the Board.

§15-1-15. Unprofessional Conduct.

The following practices shall constitute unprofessional conduct for W. Va. Code §30-5-7(9):

- 15.1. The illegal use, accessing, or disclosure of protected health information and confidential information;
- 15.2. Failure to maintain adequate records, systems, and security to protect against the illegal use or disclosure of protected health information and confidential information;
- 15.3. Failure to maintain adequate records to account for disclosures of protected health information and confidential information;
- 15.4. Engaging in conduct likely to deceive, defraud, or harm the public;
- 15.5. Demonstrating a willful or careless disregard for the health, welfare, or safety of a patient;
- 15.6. Engaging in conduct, which substantially departs from the standards of care ordinarily exercised by a licensee with proof of actual injury not having to be established;
- 15.7. Providing a drug for which a prescription order from a practitioner is required without having received a prescription drug order for the drug;

15CSR1

15.8. Willfully and knowingly failing to maintain complete and accurate records of all drugs received, dispensed, or disposed of in compliance with the federal laws and regulations and state laws and rules;

15.9. Obtaining any remuneration by fraud, misrepresentation, or deception, including, but not limited to, receiving remuneration for amending or modifying, or attempting to amend or modify, a patient's pharmacist care services, absent a clear benefit to the patient, solely in response to promotion or marketing activities;

15.10. Willfully and knowingly completing and submitting inaccurate due diligence questionnaires or attestation documents regarding the purchase or receipt of drugs from manufacturers, repackagers, third-party logistics providers, and wholesale distributors;

15.11. Knowingly filing a false or fraudulent complaint with the board;

15.12. Participation in any plan, agreement, or arrangement which eliminates or detrimentally affects the traditional relationship of physician, patient, pharmacist, and the patient's freedom of choice of professional services;

15.13. Committing any act of abuse, misconduct, or exploitation related to a licensee's practice of pharmacist care.

15.14. Consequences of Unprofessional Conduct.

15.14.1. The list of unprofessional conduct in this section is intended to govern all pharmacists, pharmacy interns, pharmacy technicians, pharmacy technician trainees, and pharmacies licensed or registered by the Board and improve the pharmacist care provided to the citizens of West Virginia.

15.14.2. The violation of the provisions of this section by a licensed pharmacist, pharmacy intern, pharmacy technician, pharmacy technician trainees, or person with a permit to operate a pharmacy may result in disciplinary action. To the extent not otherwise provided, pharmacy interns, pharmacy technician trainees, and pharmacy technicians must comply with the requirements of 15 C.S.R. 07 to the extent permitted by his or her scope of practice.

15.14.3. Any pharmacist who knowingly accepts and continues employment with any permittee who violates the rules of the Board is guilty of a violation of the rule the same as if he or she had personally engaged in the violation.

§15-1-16. Duties and Responsibilities of the Pharmacist-in-Charge.

16.1. A pharmacy may not operate without a pharmacist-in-charge (hereinafter "PIC"), who shall be designated on the application for a pharmacy license, and in each license renewal. A pharmacist may not serve as PIC unless he or she is physically present in the pharmacy a sufficient amount of time to provide supervision and control. A pharmacist may not serve as PIC for more than one pharmacy at any one time; Provided that, he or she may volunteer as the pharmacist-in-charge at a charitable clinic pharmacy while serving as a PIC in another pharmacy.

16.2. The pharmacist-in-charge has the following responsibilities:

16.2.1. The pharmacist-in-charge shall be responsible for the practice of pharmacy, as defined in this rule, at the pharmacy for which he or she is the pharmacist-in-charge. The pharmacy permit holder

15CSR1

shall be responsible for all other functions, administrative and operational, of the pharmacy. The pharmacist-in-charge may advise the pharmacy permit holder in writing of administrative and operational matters. The pharmacist-in-charge is not legally responsible if the permit holder does not follow the written advice;

16.2.2. The pharmacist-in-charge shall document and notify the pharmacy permit holder of potential violations of any statute, rule or court order existing within the pharmacy. The PIC shall provide the permit holder verbal or electronic mail communication of any violations. Documentation shall be kept on file at the pharmacy. If appropriate action has not been taken within a reasonable amount of time the pharmacist-in-charge shall provide the pharmacy permit holder written notification of the violation(s) and a copy shall be retained in the pharmacy. If appropriate action has not been taken or significant progress achieved within a reasonable amount of time the pharmacist-in-charge shall provide a written notice to the permit holder with a copy submitted to the Chief Compliance Officer at the Board. No pharmacist-in-charge shall be sanctioned by the Board for any violation of any statute, rule or court order if they have previously given documented notice to the pharmacy permit holder as outlined in this section. The pharmacy permit holder shall be responsible for such violations. Nothing precludes the pharmacist-in-charge from immediately notifying the Board of any violations;

16.2.3. Implementing quality assurance programs for pharmacy services designed to objectively and systematically monitor and evaluate the quality and appropriateness of patient care, pursue opportunities to improve patient care, and resolve identified problems. Quality assurance programs shall be designed to prevent and detect drug diversion;

16.2.4. The PIC shall implement and maintain a Pharmacy Technician Training Manual for the specific practice setting of which he or she is in charge. He or she shall supervise a training program conducted pursuant to the training manual for all individuals employed by the pharmacy who will assist in the practice of pharmacy. The PIC shall maintain a record of all technicians successfully completing the pharmacy's technician training program and shall attest to the Board, in a timely manner, those persons who, from time to time, have met the training requirements necessary for registration with the Board;

16.2.5. Implementing policies and procedures for the procurement, storage, security, and disposition of drugs and devices;

16.2.6. Assuring that all pharmacists and pharmacy interns employed at the pharmacy are currently licensed and that all pharmacy technicians employed at the pharmacy are currently registered with the board;

16.2.7. Notifying the board immediately of any of the following changes:

16.2.7.a. Change of employment or responsibility as the PIC;

16.2.7.b. Change of ownership of the pharmacy;

16.2.7.c. Change of address of the pharmacy;

16.2.7.d. Permanent closing of the pharmacy which shall be accompanied with a statement of the location where records will be retained for the required time period; or

16.2.7.e. The separation of employment of any pharmacist, pharmacy intern, pharmacy technician, or pharmacy technician trainee for any confirmed drug-related reason, including but not limited to, adulteration, abuse, theft, or diversion.

15CSR1

16.2.7.f. Notification shall include the reason for the termination. If it is the employment of the Pharmacist-in-Charge that is terminated, the owner and/or pharmacy permit holder shall immediately notify the Board of Pharmacy.

16.2.8. Making or filing any reports required by state or federal laws, rules, and regulations;

16.2.9. Responding to the board regarding any warning notice issued by the Board. The Board shall provide notification of the issuance of the warning notice to the pharmacy permit holder;

16.2.10. Implementing policies and procedures for maintaining the integrity and confidentiality of prescription information and patient health care information, or verifying their existence and ensuring that all employees of the pharmacy read, sign, and comply with the established policies and procedures; and

16.2.11. Providing the board with prior written notice of the installation or removal of an Automated Pharmacy System. The notice shall include, but is not limited to:

16.2.11.a. The name and address of the pharmacy;

16.2.11.b. The location of the automated equipment; and

16.2.11.c. The identification of the responsible pharmacist.

16.3. The PIC shall be assisted by a sufficient number of pharmacists and pharmacy technicians as may be required to competently and safely provide pharmacy services.

16.3.1. The PIC shall maintain and file with the Board, on a form provided by the Board, a current list of all pharmacy technicians assisting in the provision of pharmacy services.

16.3.2. The PIC shall implement written policies and procedures to specify the duties to be performed by pharmacy technicians. The duties and responsibilities of these personnel shall be consistent with their training and experience. These policies and procedures shall specify that pharmacy technicians are to be personally and directly supervised by a pharmacist stationed within the same work area who has the ability to control and who is responsible for the activities of pharmacy technicians, and that pharmacy technicians are not assigned duties that may be performed only by a pharmacist.

§15-1-17. Manner of Issuance of a Prescription.

17.1. A prescription to be valid, shall be issued for a legitimate medical purpose by a practitioner acting within the course of legitimate professional practice, and shall bear the preprinted, stamped, typed, or manually printed name, address and telephone number of the prescribing practitioner. If it is a prescription for a controlled substance listed in Schedules II through V, then it shall also contain the prescriber's DEA registration number, including any suffix. The National Provider Identification (NPI) number shall be required on all valid prescriptions beginning January 1, 2012.

17.1.1. A pharmacist shall receive the communication of a prescription. A pharmacist may accept a prescription, including that for a controlled substance listed in Schedules II through V, that is communicated in written form or by E-prescribing. A pharmacist may accept a prescription, including that for a controlled substance listed in Schedules III through V, and, in certain situations, that for a controlled substance listed in Schedule II, that is communicated orally (including telephone voice communication) or by way of electronic transmission other than E-prescribing.

15CSR1

17.1.2. If communicated orally or by way of electronic transmission other than E-prescribing, the pharmacist shall immediately reduce the prescription to a form that may be maintained for the time period required by any applicable federal and State of West Virginia laws and rules.

17.1.3. A prescription blank for a controlled substance shall not contain the preprinted name of a controlled substance or the written, typed or rubber-stamped name of a controlled substance until the prescription blank is signed, dated and issued to a patient.

17.1.4. A prescription for a Schedule II controlled substance may be communicated orally or by way of electronic transmission other than E-prescribing only in the following situations and with the following restrictions. Otherwise, a prescription for a Schedule II controlled substance shall be communicated in written form or by E-prescribing.

17.1.4.a. A prescription for a Schedule II controlled substance may be communicated by the practitioner or the practitioner's agent by way of electronic transmission, provided the original written prescription, signed by the practitioner, is presented to the pharmacist for review prior to the actual dispensing of the controlled substance, except the hard copy of the electronic transmission may serve as the original, written prescription in the following instances:

17.1.4.a.1. The prescription for a Schedule II narcotic substance is to be compounded for the direct administration to a patient by parenteral, intravenous, intramuscular, subcutaneous, or intraspinal infusion;

17.1.4.a.2. The prescription for a Schedule II controlled substance is for a resident of a Long Term Care Facility; or

17.1.4.a.3. The prescription for a Schedule II controlled substance is for a patient under the care of a hospice certified by Medicare or licensed by the state. The practitioner or Practitioner's agent shall note on the prescription that the patient is a hospice patient.

17.1.6. In the case of an emergency situation, a prescription for a Schedule II controlled substance may be communicated by the practitioner orally or by way of electronic transmission, provided that if the prescribing practitioner is not known to the pharmacist, he or she shall make a reasonable effort to determine that the oral authorization came from a registered practitioner, which may include a callback to the practitioner using the practitioner's phone number as listed in the telephone directory and other good faith efforts to insure his identity; and:

17.1.6.a. The quantity prescribed and dispensed is limited to the amount adequate to treat the patient during the emergency period (dispensing beyond the emergency period must be pursuant to a written prescription signed by the prescribing practitioner);

17.1.6.b. The orally communicated prescription is immediately reduced to writing by the pharmacist, or, if necessary, the prescription communicated by way of electronic transmission is immediately reduced to a hard copy;

17.1.6.c. Within seven days after authorizing an emergency oral prescription, the practitioner has a written prescription for the emergency quantity prescribed delivered to the dispensing pharmacist. The prescription shall have written on its face "Authorization for Emergency Dispensing" and the date of the orally or electronically transmitted prescription. The written prescription may be delivered to the pharmacist in person or by mail, but if delivered by mail, it must be postmarked within the seven-day period. Upon receipt, the dispensing pharmacist shall attach this written prescription to the emergency oral prescription which had earlier been reduced to writing or to the hard copy of the electronically transmitted

15CSR1

prescription. The pharmacist shall notify the nearest office of the U.S. Drug Enforcement Administration if the prescribing practitioner fails to deliver a written prescription.

17.1.7. A prescribing practitioner may authorize his or her agent to communicate a prescription orally or by way of electronic transmission either directly or through an electronic data intermediary to a pharmacist in a licensed pharmacy, provided:

17.1.7.a. The identity of the transmitting agent is included in the order;

17.1.7.b. The prescription is transmitted either directly or through an electronic data intermediary to a pharmacist in a licensed pharmacy of the patient's choice with no unauthorized person having access to the prescription;

17.1.7.c. The prescription identifies the transmitter's phone number for verbal confirmation, the time and date of transmission, and the identity of the pharmacy intended to receive the transmission, as well as any other information required by federal or state law;

17.1.7.d. The pharmacist exercises professional judgment regarding the accuracy, validity, and authenticity of the prescription communicated by way of electronic transmission; and

17.1.7.e. All electronic equipment for receipt of prescriptions communicated by way of electronic transmission is maintained so as to ensure against unauthorized access.

17.1.8. Electronic Data Intermediaries.

17.1.8.a. Electronic data intermediaries may transmit electronic prescriptions, prescription refill authorization requests, communications, and other patient care information using a secure infrastructure between an authorized prescribing practitioner and a pharmacy of the patient's choice.

17.1.8.b. Electronic data intermediaries shall meet the following requirements for electronically transmitted prescription orders, refill authorization requests, communications and other transmitted patient care information:

17.1.8.b.1. Maintain the confidentiality and security of transmitted information as required by applicable federal and state laws.

17.1.8.b.2. Transmit prescriptions to the pharmacy of the patient's choice.

17.1.8.b.3. Maintain the integrity, privacy, and security of archived copies of the electronic information related to the transmissions as required by applicable state and federal laws, including maintaining them as confidential information.

§15-1-18. Labeling.

18.1. All drugs dispensed by a licensed pharmacy shall be labeled according to the requirements of this section, and shall include all information required by federal law or regulation or state law or rule.

18.1.1. All drugs dispensed for use by inpatients of a hospital or other health care facility, where the drug is not in the possession of the ultimate user prior to administration, shall meet the following requirements:

15CSR1

18.1.1.a. The label of a single-unit package of an individual-dose or unit-dose system of packaging of drugs shall include:

18.1.1.a.1. The name of the drug;

18.1.1.a.2. The route of administration, if other than oral;

18.1.1.a.3. The strength and volume, where appropriate, expressed in the metric system whenever possible;

18.1.1.a.4. The control number and beyond-use-date;

18.1.1.a.5. Special storage conditions, if required; and

18.1.1.b. Identification of the repackager by name or by license number shall be clearly distinguishable from the rest of the label.

18.1.1.c. When a multiple-dose drug distribution system is utilized, including dispensing of single unit packages, the drugs shall be dispensed in a container to which is affixed a label containing the following information:

18.1.1.c.1. Identification of the dispensing pharmacy;

18.1.1.c.2. The patient's name;

18.1.1.c.3. The date of dispensing;

18.1.1.c.4. The name of the drug dispensed; and

18.1.1.c.5. The strength, expressed in the metric system whenever possible.

18.1.2. All drugs dispensed to inpatients for self-administering shall be labeled in accordance with subdivision 22.18.1.4 of this section.

18.1.3. Whenever any drugs are added to parental solutions, the admixtures shall bear a distinctive label indicating:

18.1.3.a. The name of the solution, the lot number, and the volume of the solution;

18.1.3.b. The patient's name;

18.1.3.c. The infusion rate;

18.1.3.d. The bottle sequence number or other system control number;

18.1.3.e. The name and quantity of each additive;

18.1.3.f. The date of the preparation;

18.1.3.g. The beyond-use date and time of parental admixture; and

18.1.3.h. Ancillary precaution labels.

15CSR1

18.1.4. All drugs dispensed to ambulatory or outpatients shall have a label affixed to the container in which the drug is dispensed, including:

18.1.4.a. The name (including store number, if any), address, and telephone number of the pharmacy dispensing the drug;

18.1.4.b. The name of the patient for whom the drug is prescribed; or, if the patient is an animal, the last name of the owner, name and species of the animal; Provided that, if the prescription is for expedited partner therapy as permitted by W. Va. Code §16-4F-1 *et seq.*, then the words “Expedited Partner Therapy” or the designation “EPT” may be written for the name of the patient;

18.1.4.c. The name of the prescribing practitioner;

18.1.4.d. Directions stated on the prescription order, and medication purpose/indication if included on the prescription order;

18.1.4.e. The date filled;

18.1.4.f. Any cautions which may be required by federal or state law;

18.1.4.g. The prescription number of the prescription drug order;

18.1.4.h. The name or initials of the dispensing pharmacist;

18.1.4.i. The proprietary or generic name of the drug dispensed, and its strength;

18.1.4.i.1. When dispensing an equivalent drug product, the word “substitution” or the letters “sub” shall appear on the label affixed to the container in which the drug is dispensed, followed by the generic name and manufacturer, or reasonable abbreviation, and/or distributor of the chosen product. This requirement only applies to single-entity, multiple-source drugs;

18.1.4.i.2. When dispensing a single-entity, single-source drug, the trade name of the prescribed drug may also appear on the label, and the generic name of the prescribed drug may also appear on the label;

18.1.4.i.3. When dispensing a fixed combination product, the United States Pharmacopeia’s publication of Pharmacy Equivalent Names (PEN) for fixed combination products is the official list of abbreviations for labeling, and is the approved abbreviation for identifying the combination product dispensed;

18.1.4.j. Drug quantity;

18.1.4.k. Number of remaining refills;

18.1.4.l. Auxiliary information;

18.1.4.m. The name of the manufacturer or distributor of the drug; and

18.1.4.n. The beyond-use date.

15CSR1

18.1.5. No radiopharmaceutical may be dispensed unless a label is affixed to the immediate container bearing the following information:

- 18.1.5.a. The standard radiation symbol;
- 18.1.5.b. The words “Caution- Radioactive Material”; and
- 18.1.5.c. The prescription number.

18.1.6. No radiopharmaceutical may be dispensed unless a label is affixed to the outer or delivery container bearing the following information:

- 18.1.6.a. The standard radiation symbol;
- 18.1.6.b. The words “Caution- Radioactive Material”;
- 18.1.6.c. The radionuclide and chemical form;
- 18.1.6.d. The activity and date and time of assay;
- 18.1.6.e. The volume, if in liquid form;
- 18.1.6.f. The requested activity and the calibrated activity;
- 18.1.6.g. The prescription number;
- 18.1.6.h. The patient’s name or space for the patient’s name. When the patient’s name is not available at the time of dispensing, a 72 hour exemption is allowed to obtain the name of the patient. No later than 72 hours after dispensing the radiopharmaceutical, the pharmacist shall obtain the patient’s name and it shall become a part of the prescription to be retained for a period of five years;
- 18.1.6.i. The name and address of the nuclear pharmacy;
- 18.1.6.j. The name of the practitioner; and
- 18.1.6.k. The lot number of the prescription.

§15-1-19. Pharmacist Consultants.

19.1. Locations requiring a pharmacist to serve as a pharmacy consultant:

- 19.1.1. Hospital or medical clinic without a pharmacy;
- ;
- 19.1.2. Weight loss clinic (registered as a facility);
- 19.1.3. Urgent care clinic;
- 19.1.4. Long Term Care Facility, including but not limited to, skilled nursing facilities, intermediate nursing facilities, nursing homes, extended care facilities, assisted living facilities, rest homes, and personal care centers;

15CSR1

19.1.5. Opioid Treatment Facility or Medication Assisted Treatment Facility;

19.1.6. Jails and correctional facilities.

19.2. Locations not required to have a pharmacist consultant;

19.2.1. Teaching institutions/researcher;

19.2.2. Emergency services;

19.2.3. Law enforcement;

19.2.4. Veterinary hospital/clinic

19.2.5. Dental practice

19.2.6. Humane society

19.3. Requirements and registration.

19.3.1. A pharmacist providing consulting services shall be registered as a consultant pharmacist with the Board and shall be licensed to practice pharmacy in West Virginia.

19.3.2. Every pharmacist providing pharmacy consulting services shall apply annually on the prescribed form, to register with the Board as follows:

19.3.2.a. The consultant pharmacist shall file an application with the Board for each institution, place or person to whom consulting services are provided;

19.3.2.b. The application shall contain, but is not limited to:

19.3.2.b.1. The name, address and phone number of the applying consultant and his or her license number;

19.3.2.b.2. The name, address, phone number and type of institution, entity or person receiving the consulting services;

19.3.2.b.3. A description of the services to be provided by the consultant; and

19.3.2.b.4. The name and signature of the facility administrator.

19.3.3. The consultant pharmacist shall immediately report to the Board any change in the data previously placed on the application for registration as a consultant. If the consulting arrangement is discontinued the consultant pharmacist shall immediately return the consulting permit to the Board.

19.3.4. The fee for registration as a consultant is \$20.00 annually for each registration.

19.4. Responsibilities.

15CSR1

19.4.1. A pharmacist consultant shall document by date and time, in a permanent log book, his or her activities for each place where he or she is registered. This log book shall be present in each facility for which the consultant pharmacist is registered and shall be available for inspection by the Board at any time.

19.4.2. The pharmacist consultant shall initiate and maintain, in each facility, appropriate records and procedures for the receipt, storage and disposition of all drugs including but not limited to:

- 19.4.2.a. Prescriptions;
- 19.4.2.b. Floor stock;
- 19.4.2.c. Emergency boxes or kits;
- 19.4.2.d. Investigational drugs;
- 19.4.2.e. Samples; and
- 19.4.2.f. Outdated or discontinued drugs.

19.4.3. The pharmacist consultant shall maintain a Policy and Procedures Manual for pharmaceutical services. The Manual shall be available to all inspectors and available to patient care providers for their guidance in drug handling. The manual shall include, but not be limited to, provisions for the following:

- 19.4.3.a. Transcribing drug orders and prescription ordering;
- 19.4.3.b. Prescription delivery system and in-house verification;
- 19.4.3.c. Drug recall;
- 19.4.3.d. Automatic stop orders;
- 19.4.3.e. Formulary or standards for drug quality;
- 19.4.3.f. Systematic review of drug orders;
- 19.4.3.g. Reconciliation of controlled substances;
- 19.4.3.h. Disposition by the following means of prescriptions not totally consumed by the patient:
 - 19.4.3.h.1. Return to pharmacy for credit; and
 - 19.4.3.h.2. Destruction by the pharmacist in the presence of a registered nurse; and
- 19.4.3.i. Drug education for other personnel.

19.4.4. The pharmacist consultant shall maintain an appropriate drug reference library for use by other health care personnel.

15CSR1

19.4.5. The pharmacist consultant shall ensure compliance with all applicable laws and regulations, both state and federal.

19.4.6. The pharmacist consultant shall make every effort to separate consulting duties from dispensing duties. Remuneration shall be comparable to that charged by a pharmacist consultant not associated with the supplier of drugs or devices.

19.4.6.a. The pharmacist or his or her employer shall receive remuneration directly from the facility to which he or she is providing the service.

19.4.6.b. If the pharmacist consultant has any financial interest in the pharmacy providing drugs or devices to the facility he or she may not provide consulting service in order to obtain an agreement to be the supplier.

19.4.7. Nothing in this rule precludes a patient in a skilled or intermediate nursing facility, or other voluntarily entered facility, from free choice of pharmacy services.

§15-1-20. Specialized Dispensing Systems.

20.1. Definition.

20.1.1. Specialized dispensing systems are those systems other than traditional bottle systems used to provide controlled administration of drugs, for oral administration, to ambulatory patients, and to patients and residents of health institutions.

20.2. Types.

20.2.1. A unit dose dispensing system is a system in which each individual unit of medication dosage form is in a separate container, which is intended to be placed in a larger prescription container which is complete with prescription labeling and contains several unit doses. Each individual unit-dose container shall be labeled with the following:

20.2.1.a. The name and strength of the drug;

20.2.1.b. The name of the manufacturer or the packager;

20.2.1.c. The lot number; and

20.2.1.d. The beyond-use date.

20.2.2. A unit of use system is a system in which all doses containing different medications to be administered at a given time are placed together in a single package, or packet, which is intended to be placed in a larger prescription container which is complete with prescription labeling and contains several unit of use packets. Each unit of use packet shall be labeled with the following:

20.2.2.a. The name and strength of each drug contained in the unit of use packet;

20.2.2.b. The name of the manufacturer or the packager of each drug in the unit of use packet;

20.2.2.c. The lot number of each drug in the unit of use packet; and

20.2.2.d. The expiration date of each drug in the unit of use packet;

15CSR1

20.2.3. Punch card packaging is a system, which does not constitute unit dose packaging, in which several doses of the same drug are packaged in a card, which is a prescription container, in which each dose has its own space and may be removed without disturbing the packaging for the remaining doses. A punch card shall be labeled with the following:

- 20.2.3.a. The name and strength of the drug contained in the punch card;
- 20.2.3.b. The name of the manufacturer or packager of the drug contained in the punch card;
- 20.2.3.c. The lot number of the drug contained in the punch card;
- 20.2.3.d. The expiration date of the drug contained in the punch card; and
- 20.2.3.e. All other information required to be on the label of a completed prescription order.

20.3.1. All extemporaneous unit dose, unit of use, punch card or any other specialized packaging shall be done by pharmacists, pharmacy interns, pharmacy technicians or pharmacy technician trainees under the direct supervision of a pharmacist.

20.3.2. The beyond-use date shall not exceed:

- 20.3.2.a. Six months from the date of repackaging; or
- 20.3.2.b. The manufacturer's expiration date; whichever is earlier.
- 20.3.2.c. Except as modified in 15 C.S.R. 05.

20.3.3. These specialized packaging systems may not be used without the required prescription labeling being on the package that is intended to hold several doses for an individual patient.

20.4. Methods of supplying drugs and devices.

20.4.1. Institutions may not have drugs supplied in floor stock quantities unless a controlled substance permit is held by the institution.

20.4.2. Drugs may be supplied by prescription for individual patients.

20.4.3. Drugs, other than by prescription, may be stocked in emergency kits when the following conditions are met:

20.4.3.a. Drugs in emergency kits are to be administered only by those persons licensed to administer drugs;

20.4.3.b. The drugs in the emergency kit are of such nature that their absence would threaten the survival of the patients or intended recipients;

20.4.3.c. The contents of the emergency kit are determined by the pharmacist consultant and the medical director and the nursing director;

20.4.3.d. The emergency kit is sealed so that it is obvious if it has been opened and it is stored under secure conditions;

15CSR1

20.4.3.e. Administration of drugs from the kit is ordered by a practitioner and a record kept of administration;

20.4.3.f. Drugs stocked in the emergency kit are unit dose packaged;

20.4.3.g. Any drug used from the kit is replaced only upon a prescription or physician institution order form for the patient to which the dose was administered; and

20.4.3.h. Any emergency kit containing controlled substances is kept only at a facility holding a controlled substance permit from the Board.

§15-1-21. Institutions and Other Places Needing a Controlled Substance Permit.

21.1. Any facility, including any hospital, skilled nursing facility, intermediate nursing facility, personal care home, jail, correctional institution, emergency organization, clinic or any other place which is responsible to administer drugs to in-patients or out-patients which, may or may not, hold a permit from this Board to operate a pharmacy, shall have a permit to handle controlled substances at the facility. A practitioner whose office is his or her primary place of practice is not required to obtain a permit for the office but shall obtain a permit for any satellite offices or clinics with controlled substances on the premises.

21.2. The Board shall issue a controlled substance permit to those persons required by W. Va. Code §60A-3-301 and §60A-3-302 to possess a permit.

21.3. Fees –The fees for a controlled substance permit are as follows unless changed by statute:

- 21.3.1. Manufacturer and wholesaler \$50.00
- 21.3.2. Hospital or Clinic \$50.00
- 21.3.3. Extended care facility or nursing home \$25.00
- 21.3.4. Non-government training institution \$25.00
- 21.3.5. Non-government researcher \$25.00
- 21.3.6. Pharmacy \$10.00
- 21.3.7. Non-government jails and correctional facilities . . . \$25.00
- 21.3.8. Non-government rescue or emergency squads \$25.00
- 21.3.9. Non-government humane societies \$25.00
- 21.3.10 All government agencies or employees are exempt from paying the fee.

§15-1-22. Emergency Dispensing by Pharmacists.

22.1. If a pharmacist is unable to obtain a refill authorization from a health care professional who issued the prescription and the pharmacy at which the pharmacist works has a record of the prescription for the drug in the name of the patient who is requesting it, a pharmacist may dispense an emergency supply of a prescription drug of life-sustaining medication or continue therapy for a chronic condition of the patient, when in the professional judgement of the pharmacist, failure to dispense could result in harm to

15CSR1

the health of the patient. An amount not to exceed a 30-day supply or the standard unit of dispensing of a non-controlled substance may be provided to the patient as demonstrated by records maintained by the pharmacy. An amount not to exceed a 72-hour supply of a Schedule III, IV or V may be provided to the patient as demonstrated by records maintained by the pharmacy. A pharmacist shall not dispense a particular drug to a patient as an emergency supply more than once in any 12-month period.

22.1.1. A pharmacist who dispenses under 15 C.S.R. 01 shall:

22.1.1.a. Maintain a record of the dispensing for one year from the date of dispensing;

22.1.1.b. Notify the health professional who prescribed the initial professional within 72 hours after the drug is dispensed;

22.1.1.c. If possible, obtain authorization for additional dispensing from one of the health professionals responsible for the patient's care; and

22.1.1.d. A pharmacist who dispenses under this section may do so once per year for each particular drug.

§15-1-23. West Virginia Official Prescription Paper Program Rules.

23.1. The purpose of this section is to establish rules for the West Virginia official prescription paper program set forth at W. Va. Code §30-5-7(a)(32) for use in writing prescriptions by practitioners.

23.2. Minimum Requirements of West Virginia Official Prescription Paper. The prescription paper shall contain the following security features:

23.2.1. Shall meet all requirements issued by the Center for Medicare and Medicaid Services for a written prescription for controlled substances as required by Section 2002(b) of PL. 110-28 of the Iraq War Supplemental Appropriations Bill enacted by the United States Congress in 2007;

23.2.2. Shall contain six quantity check-off boxes printed on the form and in the following quantities shall appear:

23.2.2.a. 1-24;

23.2.2.b. 25-49;

23.2.2.c. 50-74;

23.2.2.d. 75-100;

23.2.2.e. 101-150; and

23.2.2.f. 151 and over:

Provided That, if the blank has the quantity prescribed electronically printed in both numeric and word format, then the quantity check-off boxes shall not be necessary;

23.2.3. Shall contain space for the prescriber to indicate number of refills, if any, or to indicate no refills;

15CSR1

23.2.4. Shall provide space for the patient's name and address, the prescribing practitioner's signature;

23.2.5. Shall provide space for the preprinted, stamped, typed, or manually printed name, address and telephone number of the prescribing practitioner, and the practitioner's DEA registration number and NPI number; Provided that, if a practitioner does not have authority to prescribe controlled substances, then no DEA number shall be required, and, instead, the following statement shall be printed: "No Controlled Substances Authority"; and, Provided further that, if a practitioner is a veterinarian, no NPI number shall be required;

23.2.6. Shall contain the following statement printed on the bottom of the prescription blank: "This prescription may be filled with a generically equivalent drug product unless the words 'Brand Medically Necessary' are written in the practitioner's own handwriting, on this prescription form."

23.3. Practitioners licensed to practice in this State may purchase West Virginia Official Prescription Paper as per individual orders from any vendor(s) which produces or supplies compliant West Virginia Official Prescription Paper.

23.4. On and after July 1, 2016, every written prescription written in West Virginia by a practitioner shall be written on West Virginia Official Prescription Paper. A pharmacist may not fill a written prescription from a West Virginia practitioner unless issued upon West Virginia Official Prescription Paper, except that a pharmacist may provide emergency supplies in accordance with the relevant laws and rules for emergency dispensing or other insurance contract requirements. Nothing in this section shall be construed to impact regulations regarding verbal, facsimile, electronic, or out-of-state prescription practices.

23.5. Practitioners; control and reporting of West Virginia Official Prescription Paper.

23.5.1. Adequate safeguards and security measures shall be undertaken by practitioners holding West Virginia Official Prescription Paper to assure against the loss, destruction, theft or unauthorized use of the forms. The forms may be used only by the practitioner to whom they are issued and are not transferable.

23.5.2. The Practitioner must also notify the vendor of any failure to receive West Virginia Official Prescription Paper within a reasonable time after ordering it. Further, practitioners must immediately notify the Board and vendor in writing of the loss through destruction, theft or loss, or unauthorized use of any Official Prescription Paper blanks, including:

23.5.2.a. Estimated number of blanks affected;

23.5.2.b. Control numbers if available; and

23.5.2.c. Suspected reason for destruction, theft, or loss.

23.5.3. West Virginia Official Prescription Paper does not have to come pre-printed from a vendor, but may also be created at the point of prescribing with software-generated prescriptions by printing on plain paper with secure technology accessible only by the prescriber and his or her authorized agent that results in a tamper resistant prescription as required by subsection 23.3 of this section.

§15-1-24. Practice of Telepharmacy and Telehealth services.

15CSR1

24.1. Except as otherwise provided specifically herein, the practice of telepharmacy or telehealth is permitted only as follows:

24.1.1. For a pharmacist to provide direct patient-care activities, when the patient is unable to be present in the pharmacy for a personal, face-to-face interaction, provided the pharmacist is:

24.1.1.a. Licensed to practice pharmacist care in West Virginia; or,

24.1.1.b. Licensed to practice pharmacist care in the state where the mail order pharmacy is located if dispensing prescription drugs to a patient in this State from a non-resident mail order pharmacy properly permitted as a mail order pharmacy to dispense into this State;

24.1.2. For drug regimen review of prescription orders for a patient in an institutional facility, for the pharmacist to authorize the dispensing and administration, provided the pharmacist is licensed to practice pharmacist care in West Virginia.

24.2. The practice of the health care service occurs where the patient is located at the time the telehealth services are provided;

24.2.1. The health care practitioner-patient relationship is established according to the definition of “valid patient-practitioner relationship” found in W. Va. Code §30-5-4;

24.2.2. The standard of care shall require that with respect to the established patient, the patient shall visit an in-person health care practitioner within 12 months of using the initial telehealth service or the telehealth service shall no longer be available to the patient until an in-person visit is obtained. This requirement may be suspended, in the discretion of the health care practitioner, on a case-by-case basis, and it does not apply to the following services: Acute inpatient care, post-operative follow-up checks, behavioral medicine, addiction medicine, or palliative care;

24.2.3. A prohibition of prescribing any controlled substance listed in Schedule II of the Uniform Controlled Substance Act, unless authorized by another section: *Provided*, That the prescribing limitations contained in this section do not apply to a physician or a member of the same group practice with an established patient;

24.2.4. A pharmacist, pharmacy intern, pharmacy technician or pharmacy technician trainee performing telehealth care service is subject to the code of unprofessional conduct in 15 C.S.R. 01;

24.2.5. A pharmacist, pharmacy intern, pharmacy technician or pharmacy technician trainee performing telehealth care service is subject to the Board’s discipline process as specified in 15 C.S.R. 09.

24.2.6. A pharmacist is prohibited from prescribing or dispensing an abortifacient; and

24.2.7. A pharmacist is prohibited from prescribing or dispensing gender altering medication to a person who is under 18 years of age.

24.3. The health care provider by registering to provide interstate telehealth services to patients in this state is subject to:

24.3.1. The laws regarding the profession in this state, including the state judicial system and all professional conduct rules and standards incorporated into the health care practitioner’s practice act and the legislative rules of the registering board; and

24.3.2. The jurisdiction of the board with which he or she registers to provide interstate telehealth services, including such board's complaint, investigation, and hearing process.

24.3.3. A health care professional who registers to provide interstate telehealth services pursuant to the provisions of or the requirements of this section shall immediately notify the board where he or she is registered in West Virginia and of any restrictions placed on the individual's license to practice in any state or jurisdiction.

§15-1-25. Criminal History Record Check.

25.1 Beginning July 1, 2017, and in addition to all the requirements for licensure, an applicant for an initial license to practice as a pharmacist, intern, pharmacy technician, or pharmacy technician trainee in West Virginia shall request and submit to the Board the results of a state and national criminal history record check.

25.2. The purpose of the criminal history record check is to assist the Board in obtaining information that may relate to the applicant's fitness for licensure.

25.3. In addition to the State Police, the Board may contract with and designate a company specializing in the services required by this section instead of requiring the applicant to apply directly to the West Virginia State Police or similar out-of-state agency for the criminal history records checks. Provided that any such company must utilize protocols consistent with standards established by the Federal Bureau of investigation and the National Crime Prevention and Privacy Compact.

25.4. The applicant shall furnish to the State Police, or other organization duly designated by the Board, a full set of fingerprints and any additional information required to complete the criminal history record check.

25.5. The applicant is responsible for any fees required by the State Police, or other organization duly designated by the Board, for the actual costs of the fingerprinting and the actual costs of conducting a complete criminal history record check.

25.6. The Board may require the applicant to obtain a criminal history records check from a similar Board approved agency or organization in the state of the applicant's residence if outside of West Virginia.

25.7. The applicant shall authorize the release of all records obtained by the criminal history record check to the Board.

25.8. A criminal history record check submitted in support of an application for licensure must have been requested by the applicant no earlier than 12 months immediately prior to the Board's receipt of the applicant's application for licensure.

25.9. An initial licensure application is not complete until the Board receives the results of a state and criminal history record check conducted by the State Police or another entity duly authorized by the Board. The Board shall not grant an application for licensure submitted by any applicant who fails or refuses to submit the criminal history record check required by this section.

25.10. Should criminal offenses be reported on an applicant's criminal history record check, the Board will consider the nature, severity, and recency of offenses, as well as rehabilitation and other factors on a case-by-case basis for licensure. Criminal history record checks shall be verified by a source acceptable to the Board, other than the applicant.

25.11. The results of the state and national criminal history record check may not be released to or by a private entity except:

25.11.1. To the individual who is the subject of the criminal history record check;

25.11.2. With written authorization of the individual who is the subject of the criminal history record check; or

25.11.3. Pursuant to a court order.

25.12. Criminal history record checks and related records are not public records for the purposes of Chapter 29B of the West Virginia Code.

§15-1-26. Duties and Responsibilities of a Pharmacist

It is the duty and responsibility of the pharmacist in every pharmacy to perform, at the minimum, the following duties:

26.1. To accept all new prescription orders from authorized prescribers transmitted by oral communication, immediately reduce them to writing and document the prescription by entering on the prescription order form:

26.1.1. The name of the caller;

26.1.2. The time and date of transmission; and

26.1.3. The handwritten initials of the receiver.

26.2. To dispense, deliver, or distribute a prescription drug order accurately as prescribed. For the purposes of this paragraph “accurately as prescribed” means:

26.2.1. To the correct patient (or agent of the patient) for whom the drug or device was prescribed;

26.2.2. With the correct drug in the correct strength, quantity, and dosage form ordered by the practitioner, unless converting a prescription order in accordance with W. Va. Code §30-5-35; a pharmacist may substitute a generic drug pursuant to W. Va. Code §30-5-12b; and

26.2.3 With correct labeling (including directions for use) as ordered by the practitioner;

26.3. To ensure that his or her initials are on all prescription labels dispensed while he or she is on duty, whether prepared by him or her or prepared by a pharmacy technician under his or her supervision;

26.4. To ensure that his or her initials are on all prescription order forms dispensed while he or she is on duty, whether prepared by him or her or prepared by a pharmacy technician under his or her supervision;

26.5. To counsel or inform patients about their drugs, which may include supplemental media according to the pharmacist’s professional judgment, to the patient, care giver, or agent. An offer to counsel shall be made by the pharmacist or designee in an oral communication with the patient, care giver or agent who presents a new prescription order, unless in the professional judgment of the pharmacist it is

15CSR1

permissible for the offer to counsel to be made in a written communication, by telephone, in person, or in a manner determined by the pharmacist to be appropriate. The exercise of and reasons for this judgment shall be documented including the hand-written pharmacist's initials. An offer to counsel has not been made by a mere question of whether the patient has any questions.

26.5.1. In those cases, when the offer to counsel, as described in this subsection, has been accepted, a pharmacist who provides pharmacist care to patients shall discuss with the patient or care giver or agent who presents a new prescription order, any matter which in the exercise of the pharmacist's professional judgment he or she considers significant, which may or may not include the following:

26.5.1.a. The name of and a description of the medication;

26.5.1.b. The dosage form, route of administration, degree, and duration of drug therapy;

26.5.1.c. Special directions and precautions for preparation, administration, and use by the patient;

26.5.1.d. Common severe side or adverse effects or interactions and therapeutic contraindications that may be encountered, including their avoidance and the actions required if they occur;

26.5.1.e. Techniques for self-monitoring drug therapy;

26.5.1.f. Proper storage and handling;

26.5.1.g. Prescription refill information; and

26.5.1.h. Any action to take in the event of a missed dose.

26.5.2. Nothing in this subsection requires a pharmacist to provide consultation if the patient, care giver, or agent does not accept the offer to counsel. If counseling is refused it shall be documented, followed by the initials of the recording pharmacist. Patient counseling is not required for inpatients of a hospital or institution where other licensed health care workers are authorized to administer the drugs;

26.6. To make a reasonable effort to obtain, record, and maintain at least the following information at the individual pharmacy:

26.6.1. The patient's name, address, telephone number, date of birth or age, and gender;

26.6.2. The patient's individual history including disease states, known allergies and drug reactions, and a comprehensive list of medications and relevant devices; and

26.6.3. The pharmacist's comments regarding the patient's therapy;

26.7. To perform all of the functions in this section;

26.8. To adequately supervise all pharmacy interns, registered pharmacy technicians and pharmacy technician trainees; and

26.9. To perform any other functions of any nature or kind which:

26.9.1. Require the knowledge, ability or skill of a licensed pharmacist; and

15CSR1

26.9.2. Attempt to improve the therapeutic outcome to the patient of the pharmacist care provided by the pharmacist.

26.10. No pharmacist, pharmacy intern, or pharmacy technician shall compound or dispense any prescription order which, in his or her judgment or professional opinion, contains any error, irregularity or ambiguity. The pharmacist shall hold a conference with the prescriber before dispensing, if there is any doubt that the prescription order is not legal or correct or issued for a legitimate medical purpose.

26.11. No person practicing pharmacist care shall engage in conduct, in the practice of pharmacy or in the operation of a pharmacy, which tends to reduce the public confidence in the ability and integrity of the profession of pharmacy, or endangers the public health, safety and welfare; nor shall he or she interfere in the profession of pharmacist care or offer pharmaceutical services under any terms or conditions which tend to impair the free and complete exercise of the professional skill and judgement of another pharmacist. A person practicing pharmacist care shall at all times practice his or her profession in conformity with federal and state laws and regulations and rules of this Board.

26.12. No pharmacist, pharmacy technician, or pharmacy intern shall attempt to diagnose any disease, illness, or disorder except as permitted in §30-5-10(15). This does not preclude evaluation of a patient after a diagnosis is made by a practitioner. The pharmacist may advise on the merits and quality of over-the-counter (OTC) products.